We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
In investor discussions surrounding GSK (GSK Plc) on ADVFN, there is a mix of anticipation and caution as the company approaches its earnings report scheduled for February 5th. Analysts predict a 3.2% decline in quarterly revenue, forecasting a drop from $9.99 billion a year ago to approximately $9.677 billion. Despite this potential dip in revenue, some investors express optimism about earnings performance, with one user noting, “Wouldn't be surprised if they beat on the earnings,” highlighting a sentiment that GSK may outperform expectations even amid declining revenues.
A significant development discussed is the recent authorization from the European Commission for GSK's ViiV Healthcare to use its long-acting injectable regimen, Vocabria and Rekambys, for adolescents living with HIV-1. This authorization indicates a growing portfolio in GSK’s pharmaceutical offerings, which could bolster future revenue streams. The overall investor sentiment leans towards cautious optimism, with a broader discussion of GSK’s financial health and market position, underlined by its substantial market capitalization of $71 billion. Overall, investors are closely monitoring the upcoming earnings report for insights into the company’s resilience and strategic direction.
Show more
GSK plc is anticipating an increase in earnings for 2024, reflecting a positive outlook amid concerns surrounding its vaccines in the US market. While both GSK and market analysts expect growth, there are looming geopolitical threats that could impact the firm’s performance, particularly concerning its vaccine portfolio. These insights suggest that GSK is navigating a challenging landscape while aiming to bolster its financial standing.
In another administrative update, GSK disclosed its total voting rights, reporting a share capital consisting of over 4.3 billion ordinary shares, with approximately 169 million shares held in treasury. The total number of voting rights available to shareholders stands at about 4.15 billion, which is critical for shareholders in adherence to regulatory reporting requirements. This transparency is in line with guidelines set by the Financial Conduct Authority, ensuring that the market remains informed about the company's capital structure.
Show more
Good news today re. successful Phase lll Linerixibat results. |
Gecko |
Are you trying to initiate a war here Gecko ?? |
Yawn, your TDS is boring Jubber. |
The general market has got a new strain of Trump/Kennedy induced diarrhoea |
Yes good news followed by bad news, daily. |
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) |
I'll add my two pennyworth |
Interesting points made here. I'm assuming by individuals who hold significant amounts.?..the fact it has become more noteably political is intriguing. |
#743. What has that post got to do with GSK? |
Dr Biotech |
That's ok - they'll raise it again after the shareprice reaches 1500p, 1700p etc. |
Wow, I know analysts are useless but that's a big cut. |
These brokers are good for nothing at all. |
These brokers are so clever cutting price targets after the event...10yrs old could that... |
Deutsche Bank cuts target price to 1350p from 1700p |
Further falls as Tariffs hit. |
is RFK jnr's appointment likely to be acceptable to and confirmed by congress? It seems even some Republican members are extremely sceptical of the anti-vax and FDA rhetoric, believing that vaccination is probably the biggest medical advance of all time after clean drinking water. |
I had this sell off attributed to the legal difficulties currently being experienced by AZN big wigs in China,this was then followed by the appointment of a Health Secretly in the USA who is as deluded as trump. |
First UK case was jan 2020. Part of the problem with Covid whilst obviously a serious virus, was the misinformation given by the likes of Zero Hedge and reposted by useful idiots on other forums. Doing Russia's bidding, but too thick to realise. Would have helped of course if the Chinese had been more honest and open. |
Washingmachine 16 Nov '24 - 07:08 - 33722 |
And he’s still had a far better life than 99 percent .. |
Oh and Taylor swift for the teenys |
Type | Ordinary Share |
Share ISIN | GB00BN7SWP63 |
Sector | Pharmaceutical Preparations |
Bid Price | 1,374.50 |
Offer Price | 1,375.00 |
Open | |
Shares Traded | 0.00 |
Last Trade | 00:00:00 |
Low - High | - |
Turnover | 30.33B |
Profit | 4.93B |
EPS - Basic | 1.1889 |
PE Ratio | 11.56 |
Market Cap | 57.2B |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads